今日盘中，昭衍新药（06127.HK）股价大跌5.01%，引发市场关注。分析人士认为，这可能与公司近期发布的第三季度业绩报告有关。
根据公司公告，昭衍新药2025年第三季度单季度主营收入为3.16亿元人民币，同比下降34.87%；单季度归母净利润1977.37万元人民币，同比下降80.11%；单季度扣非净利润599.26万元人民币，同比下降92.94%。业绩大幅下滑可能是导致投资者信心受挫的主要原因。
值得注意的是，尽管单季度业绩表现不佳，但昭衍新药2025年前三季度整体业绩仍实现扭亏为盈。公司前三季度实现营业收入9.85亿元人民币，归母净利润8070.61万元人民币，而去年同期为亏损7030.71万元人民币。然而，市场似乎更关注公司短期业绩压力，这可能解释了今日的股价下跌。公司方面表示，业绩受到市场竞争加剧、订单价格下滑等因素影响，导致实验室服务业务利润空间进一步收窄。投资者可能需要关注公司未来的业务发展策略和市场竞争态势。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.